Synta66
规格
| Cas Number | 835904-51-3 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 77.5 mg/mL (219.95 mM; Need ultrasonic) |
| 过滤标签 | CRAC Channel,膜转运器/离子通道 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | Synta66 是形成 CRAC 通道孔的贮存操作钙离子通道 Orai 的抑制剂，可用于神经系统疾病的研究。 |
| 英文描述 |
Synta66 is an inhibitor of store-operated calcium entry channel Orai , which forms the pore of the CRAC channel, and used for the research of neurological disease . In Vitro Synta66 is an inhibitor of Orai, which forms the pore of the CRAC channel. Synta66 (10 μM) attenuates peak SOCE in Müller glia. Synta66 (10 μM) prevents orai channels mediating the residual SOC current in Trpc1 −/− Müller cells. Synta66 (10 μM) nearly completely blocks the Ca 2+ entry signal evoked by CaCl 2 addition, whereas it moderately reduces Ca 2+ mobilization from stores with 10% to 30% in platelet. Synta66 (10 μM) suppresses human platelet activation in plasma and whole-blood thrombus formation. Synta66 (10 μM) also inhibits murine platelet responses and thrombus formation. Synta66 (10 μM) inhibits LAD2 human mast cell line. Synta66 (10 μM) significantly inhibits FcεRI stimulated histamine and TNFα secretion, and has differential effects on FcεRI stimulated prostaglandin D2 and cytokine release in human lung mast cells (HLMCs). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Orai |